Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSuzanne LentzschMRM. Richardson

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows increased renal response and lower ESRD risk with daratumumab therapy in MIDD.

Key Points

  • Daratumumab treatment improved renal response, showing 77% improvement in eGFR for treated patients.
  • Median eGFR was similar in both daratumumab and non-daratumumab groups at diagnosis.
  • Observational analysis highlighted the significance of daratumumab in prolonging renal function and reducing ESRD progression.
  • Further studies are needed to establish daratumumab's role in treating monoclonal immunoglobulin deposition disease.

Cite This Study

Lentzsch et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236de97https://doi.org/10.1182/blood-2025-2194
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China2025
  2. 2Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab2025
  3. 3Real-world outcomes of standard and modified daratumumab-based therapy in AL amyloidosis: A cohort study from a multidisciplinary program in south India2025
  4. 4Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience2025
  5. 5Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy2025